featured Engagements
Biopharmaceutical Reasonable Royalties on Trial
When our client, a biopharmaceutical company, had exclusively licensed a patent for a novel type of cancer immunotherapy, a competitor undertook substantial efforts to be first to market for its lead indication despite being aware of potential infringement claims against its therapy. Upon the competitor achieving FDA approval, our client filed patent infringement claims. After an eight-day trial, the jury returned a verdict in favor of our client with a damages award that precisely matched the trial testimony.